279 related articles for article (PubMed ID: 32295072)
1. Towards Physiologically and Tightly Regulated Vectored Antibody Therapies.
Page A; Fusil F; Cosset FL
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32295072
[TBL] [Abstract][Full Text] [Related]
2. Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors.
Page A; Hubert J; Fusil F; Cosset FL
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576154
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
4. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
[TBL] [Abstract][Full Text] [Related]
5. Progress and challenges towards CRISPR/Cas clinical translation.
Rosenblum D; Gutkin A; Dammes N; Peer D
Adv Drug Deliv Rev; 2020; 154-155():176-186. PubMed ID: 32659256
[TBL] [Abstract][Full Text] [Related]
6. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
Wilbie D; Walther J; Mastrobattista E
Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
[TBL] [Abstract][Full Text] [Related]
7. Applications of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) as a Genetic Scalpel for the Treatment of Cancer: A Translational Narrative Review.
Mondal R; Brahmbhatt N; Sandhu SK; Shah H; Vashi M; Gandhi SK; Patel P
Cureus; 2023 Dec; 15(12):e50031. PubMed ID: 38186450
[TBL] [Abstract][Full Text] [Related]
8. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
9. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
10. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
11. Engineered CRISPR Systems for Next Generation Gene Therapies.
Pineda M; Moghadam F; Ebrahimkhani MR; Kiani S
ACS Synth Biol; 2017 Sep; 6(9):1614-1626. PubMed ID: 28558198
[TBL] [Abstract][Full Text] [Related]
12. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs.
Rittiner J; Cumaran M; Malhotra S; Kantor B
Front Bioeng Biotechnol; 2022; 10():1035543. PubMed ID: 36324900
[TBL] [Abstract][Full Text] [Related]
14. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
15. Gene editing and CRISPR in the clinic: current and future perspectives.
Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
[TBL] [Abstract][Full Text] [Related]
16. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection].
Wang YD; Liang QF; Li ZY; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324
[TBL] [Abstract][Full Text] [Related]
17. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
Shalaby K; Aouida M; El-Agnaf O
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
[TBL] [Abstract][Full Text] [Related]
18. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
Yu W; Wu Z
Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
[TBL] [Abstract][Full Text] [Related]
19. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
20. Molecular and therapeutic effect of CRISPR in treating cancer.
Rodrigo S; Senasinghe K; Quazi S
Med Oncol; 2023 Jan; 40(2):81. PubMed ID: 36650384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
